MedTrace Logo

Effects of Aliskiren in Elderly Hypertensive Chronic Kidney Disease (CKD) Patients

NCT01284114 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2012-10-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether aliskiren is effective in the treatment of blood pressure, hear function, renal function in elderly hypertensive chronic kidney disease (CKD) patients.

Conditions

Interventions

DRUG

Aliskiren

150mg/day for all as initial dose, 300mg/day for the patients that still show hypertension(above 140/90mmHg)after one month 150mg treatment,oral,on 6 months

Sponsors & Collaborators

  • Jichi Medical University

    lead OTHER

Principal Investigators

  • Yoshiyuki Morishita, MD, PhD · Division of Nephrology, Department of Medicine, Jichi Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01284114 on ClinicalTrials.gov